Xeris Pharmaceuticals Inc (XERS) Given Average Recommendation of “Buy” by Analysts

Xeris Pharmaceuticals Inc (NASDAQ:XERS) has been assigned an average rating of “Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $23.67.

Several brokerages have recently weighed in on XERS. Leerink Swann began coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set an “outperform” rating and a $24.00 price objective on the stock. Mizuho began coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set a “buy” rating on the stock. Jefferies Financial Group began coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set a “buy” rating and a $23.00 price objective on the stock. Royal Bank of Canada started coverage on shares of Xeris Pharmaceuticals in a report on Monday, July 16th. They set an “outperform” rating and a $24.00 price objective on the stock. Finally, Zacks Investment Research upgraded shares of Xeris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 29th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA purchased a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $2,481,000. Redmile Group LLC purchased a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $45,792,000. OppenheimerFunds Inc. purchased a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $18,980,000. Citadel Advisors LLC purchased a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $214,000. Finally, Dean Capital Investments Management LLC purchased a new position in Xeris Pharmaceuticals in the second quarter valued at approximately $563,000. Hedge funds and other institutional investors own 45.89% of the company’s stock.

Shares of XERS stock opened at $18.55 on Friday. Xeris Pharmaceuticals has a 1-year low of $15.75 and a 1-year high of $27.98.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its quarterly earnings data on Monday, August 13th. The company reported ($3.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($2.19). The firm had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.30 million. As a group, equities analysts forecast that Xeris Pharmaceuticals will post -8.36 earnings per share for the current year.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

See Also: Initial Public Offering (IPO)

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply